RecruitingNCT07019766

National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia


Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment

9,999 participants

Start Date

Jan 1, 2000

Study Type

OBSERVATIONAL

Conditions

Summary

Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The objectives of this study are to investigate the incidence and risk factors of large granular lymphocytic leukemia (LGLL) and to analyze the treatment effectiveness, patient prognosis, and healthcare costs in China. 1. Analyze the demographic and clinical characteristics of patients with LGLL, including sex, age, disease severity, and other relevant factors. 2. Examine disease features of LGLL patients, such as biochemical and hematological indicators, LGL counts, clonality, bone marrow pathology, and cytogenetics 3. Assess treatment patterns and real-world effectiveness in LGLL patients. 4. Evaluate clinical outcomes, including hematologic response, relapse, and mortality 5. Investigate long-term prognosis, including post-discontinuation outcomes and health-related quality of life.


Eligibility

Plain Language Summary

Simplified for easier understanding

This is a long-term observational study tracking patients diagnosed with a rare type of blood cancer called Large Granular Lymphocytic Leukemia (LGLL) at a hematology hospital in China, to better understand its course and outcomes over time. **You may be eligible if...** - You have been diagnosed with LGLL (Large Granular Lymphocytic Leukemia) - You are or have been treated at the Institute of Hematology and Blood Diseases Hospital since January 1, 2000 **You may NOT be eligible if...** - You are unlikely to be available for long-term follow-up - You have alcohol or drug dependence that may affect your ability to comply - Your doctor believes there are other reasons you are not suitable for the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERA combined retrospective and prospective observational follow-up

The NICHE-LGLL will collect basic information, diagnostic and treatment information, as well as health costs information of patients from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.


Locations(1)

Red Blood Cell Diseases Center and Regenerative Medicine Center

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07019766


Related Trials